Business Context and Reporting Period
This Form 8-K is filed by Akers Biosciences, Inc. (Ticker: AKER), an emerging growth company incorporated in New Jersey. The report covers events occurring on June 21, 2019.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on a legal contingency.
Material Changes and Legal Contingency
On June 21, 2019, the Company received a complaint filed in the United States District Court for the District of New Jersey by Novotek Therapeutics Inc. and Novotek Pharmaceuticals Limited (collectively, "Novotek").
- Allegation: Breach of contract.
- Plaintiffs: Beijing-based entities Novotek Therapeutics Inc. and Novotek Pharmaceuticals Limited.
- Claimed Damages: $1,551,562.31, plus interest, disbursements, and attorneys' fees.
Management Commentary and Outlook
Management states it will contest the complaint vigorously in the interest of its shareholders. The Company expresses confidence in its legal position and indicates it is fully prepared to defend itself in court. No financial guidance or operational outlook is provided in this filing.
Investor Verification Checklist
- Verify the current status of the Novotek litigation and any subsequent court filings.
- Assess the potential impact of the $1.55 million claim plus fees on the Company's cash position.
- Review the underlying contract between Akers Biosciences and Novotek to understand the basis of the breach of contract claim.
- Monitor for any updates on the Company's legal defense strategy or settlement negotiations.